Advertisement

Topics

Canagliflozin reduces risk of renal failure, death in CKD, diabetes

06:31 EDT 16 Apr 2019 | SmartBrief

Mundipharma reported that data from Janssen's late-stage trial of Invokana, or canagliflozin, showed that use of the treatmen -More

Original Article: Canagliflozin reduces risk of renal failure, death in CKD, diabetes

NEXT ARTICLE

More From BioPortfolio on "Canagliflozin reduces risk of renal failure, death in CKD, diabetes"

Advertisement
Quick Search
Advertisement
Advertisement